Decentralized Clinical Trials (DCTs), in which clinical trial data is collected through sensors or remote monitoring devices, can deliver many benefits to pharmaceutical companies, including cost savings, better patient recruitment and retention, and improved data quality. DCTs rose to popularity during the pandemic as people around the world were advised to stay indoors. The top reason for shifting to this model is DCTs’ patient-centered focus, which makes it easier for more people from a broader geographic spread to participate in trials without the need to visit a site.
Enterprises are now shifting away from a site-anchored approach to hybrid or completely decentralized trials and looking to convert their piecemeal deployments into a comprehensive adoption strategy.
This playbook looks at 50+ DCT case studies across different therapy areas and informs enterprises about the trends, benefits, and challenges in DCT adoption to help them design a strategy for seamless DCT adoption.
Scope
Industry: life sciences
Geography: global
Contents
This report studies:
Everest Group’s view of an end-to-end unified DCT platform
Decentralized clinical trials (DCTs) were a boon during the pandemic. Pharmaceutical enterprises capitalized on the opportunity to conduct remote and virtual trials during a time when isolation was critical. However, in 2023, pharmaceutical enterpris…
